Christopher Wilfong​

Chief Operating Officer​

Chris co-founded Kronos Bio in 2017 and currently serves as COO. Additionally, he is an Operating Partner at Two River, where he has co-founded and held interim management roles in several Two River portfolio companies including Kite Pharma, Inc. (acquired by Gilead), Nile Therapeutics, Inc. (acquired by Capricor Therapeutics), and Neogene Therapeutics. Prior to Two River, Chris was a Director and led the US investment team at Trustbridge Partners, a healthcare and technology-focused growth equity firm based in China. Prior to that, he was a Consultant at Bain & Company. Chris received his Master of Business Administration from the MIT Sloan School of Management, and his Bachelor of Science in Economics from the Wharton School of the University of Pennsylvania.